This single-center, randomized, and controlled intervention study compared an acrylate skin adhesive, Epinexus TM (Mitsui Chemicals, Inc., Tokyo) with Dermabond Advanced  (Ethicon, Inc., Somerville, New Jersey). The primary endpoint was cosmetic outcome at 52 weeks after treatment (Manchester Scar Scale), and the secondary endpoints were cosmetic outcome at 4 and 26 weeks after treatment (Manchester Scar Scale), wound closure, and usability. We evaluated 59 patients (29 cases and 30 controls). Failures and adverse events were also evaluated, and 8 adverse events (5 cases and 3 controls) were reported (epidermolysis, n = 4; contact dermatitis, n = 1; eczema, n = 1; and surgical wound dehiscence, n = 2). No difference was observed between groups in cosmetic outcome at 52 and 24 weeks; however, at 4 weeks, cases showed better cosmetic outcome compared with controls. With regard to usability, the treatment duration and application time were significantly longer with Epinexus TM , and ease of application was significantly better with Dermabond Advanced  .
Introduction
Numerous methods have been developed to achieve minimal scarring after surgery. One effective method to make a scar finer and subdermal suturing, is widely used in plastic surgery to release tension on the wound edge. Tension on the wound is said to make the scar worse, and it sometimes becomes a cause of hypertrophic scaring and keloids. Because it takes more than six months for a scar to be fixed, taping is usually used after surgery to prevent worse scarring.
For skin closure, skin adhesives are sometimes used instead of skin sutures for their ease of use and lack of a need for removal of sutures or staples. Among skin adhesives, Dermabond Advanced  (Ethicon, Inc., Somerville, New Jersey) [1] [2] is used worldwide. However, the low viscosity of Dermabond Advanced  may compromise its ability to keep the wound at rest to release tension on the wound. Also, because of its low viscosity, the Dermabond Advanced  material has the potential to flow into the wound, which may disrupt wound adhesion.
Epinexus TM (Mitsui Chemicals, Inc., Tokyo), the skin adhesive used for this study, was developed to prevent these risks. It is constructed primarily with polymethylmethacrylate, and it is biocompatible with appropriate viscosity according to its polymerization by mixing a methylmethacrylate monomer, polymethylmethacrylate powder, and polymerization initiator immediately prior to use [1] . Epinexus TM is hard enough to keep the wound at rest after it becomes stiff. Therefore there were no reports using Epinexus TM in clinical use so far; we have published the results of a pilot study of Epinexus TM that showed its safety for application to the suture [2] . The current single-center, open-label, and parallel-group study compared the efficacy, safety, and cosmetic outcome of Epinexus TM with Dermabond Advanced  in 59 subjects.
Materials and Methods

Epinexus
TM
, an acrylate skin adhesive, consists of a prefilled syringe containing polymer powder, 2 prefilled vials containing monomer liquid and polymerization initiator, respectively, a transfer needle for mixing the above 3 ingredients, and an application nozzle ( Figure 1 ). The operators' technique was standardized by preliminary training based on the description in the package insert and during the first study [3] . All of the operators had experiences more than 10 years in surgery field. The patients were randomly assigned two groups (the Epinexus TM group (EG) and the Dermabond Advanced  group (DG)). The primary endpoint was cosmetic outcome at 52 weeks after treatment (Manchester Scar Scale)
[4] [5] , and the secondary endpoints were cosmetic outcome at 4 and 26 weeks after treatment (Manchester Scar Scale), wound closure, and usability. We eva- 
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Statistical Analysis
The Full Analysis Set (FAS) was defined as all enrolled subjects except those who did not use Epinexus TM or whose data were not available for the endpoints. The
Per Protocol Set (PPS) contained subjects included in the Full Analysis Set except those in whom efficacy was difficult to evaluate or who were found to meet the exclusion criteria or deviated from the protocol after enrollment.
The FAS was used for the safety analysis. Data for the safety endpoints were accumulated from the start date to the end or discontinued date of the use of weeks ± 28 days were evaluated with the Manchester Scar Scale by 2 sub-investigators. For the comprehensive evaluation of the wound, the length to the mark on the 10-cm Visual Analog Scale (VAS) was measured, and 1 cm was calculated as 1 point. The VAS score was added to the total score of the individual endpoints for the final Manchester Scar Scale result. The mean value of the scores of the 2 sub-investigators was calculated for each subject, observation time point, and endpoint, and then the mean, maximum, and minimum values were determined for each endpoint for the PPS.
To ensure the objectivity of this study, a safety and efficacy evaluation committee was established separately, in advance, to evaluate wound closure, cosmetic outcome, usability, and safety for all subjects.
Results
Of the 63 enrolled subjects, 1 was excluded because the application site was found not to meet the inclusion criteria after enrollment. As a result, the number of subjects in both the FAS and the PPS was 62 (Figure 2 ). (Table 2 ). In 4 cases (3 EG and 1 DG), erosion was observed. Two cases of non-adhesion were observed in the DG group. All cases of erosion were resolved by applying ointment to the affected sites. With regard to the evaluation of usability, usage times for both treatment and application were significantly longer in the EG (Table 3 ). The ease of application was significantly better in the DG (Table 4) .
With regard to cosmetic results, there were no significant differences between groups at 24 and 52 weeks (Table 5 and Table 6 ). However, at 4 weeks after application, the cosmetic results were significantly better in the EG (Table 7) . Five cases discontinued the observations (Table 8) . 
Discussion
The purpose of this study was to compare the efficacy and safety of Epinexus TM with Dermabond Advanced  . We observed that the EG had a higher incidence of epidermolysis. As Epinexus TM is designed to have high viscosity and to be more adherent to the skin, these features may have contributed to the increased frequency of epidermolysis. Also, because Epinexus TM is designed to fix the wound firmly, it is harder than Dermabond Advanced 
Conflicts of Interest Modern Plastic Surgery
